Sugentech: Diagnosis for All, Anytime and Anywhere in Precision Healthcare
It’s common knowledge that timely and correct diagnosis helps aid various health and clinical decisions, and the rise of in-vitro diagnostic (IVD) solutions has contributed immensely to detecting diseases, conditions, and infections cheaply and effectively. The IVD devices have found their usage in stand-alone laboratories, hospital-based laboratories, and point-of-care centres. And with the ongoing pandemic resulting in the adoption of telehealth for diagnosis, there has been a massive demand for ETC and OTC devices for home use. The current devices, such as wearables marketed as health devices, cannot be relied on for diagnosis. However, the requirement, especially during COVID-19 and beyond, is urgent. The required sophistication to develop an accurate and affordable device has been demonstrated by Sugentech, and more than 120 countries have relied on their IVD devices in these challenging times.
The 28th INNOPOLIS Research Institute’s spin-off company of the Ministry of Science and ICT in Korea, Sugentech, was established in 2011 to develop a variety of in-vitro diagnostic products to cater to the self-diagnostics home testing products (Self-testing), Point-of-care testing (POCT) products and Fully Automated Immunoblot system requirements. “We have the capability of a wide range of R&D covering bio-chemical engineering coupled with mechanical, software and IT expertise,” says Jung Eun Lee, Chief Strategy, Sales and Marketing Vice President, Sugentech. “The deep expertise and multidisciplinary capability has enabled the realisation of innovative diagnostic tools and acceleration of its development.” To distribute these BT-IT-NT Convergence Technology based IVD devices, Sugentech has established partnerships across the globe with local and global players.
The devices are integrated with the Sugentech mobile app and are composed of small but solid instruments and disposable and replicable kits.
The deep expertise and multidisciplinary capability have enabled the realisation of innovative diagnostic tools and acceleration of its development
In the telehealth scenario, simple Q&A on condition can lead to inadequate information and, later, diagnosis, and the Sugentech mobile app functions to ask the requirements of the patient, display the result while communicating with the instrument automatically, guide the patient to perform the test, and manage the data.
Sugentech has launched its first set of devices for five different kinds of female hormone testing. These devices are based on Sugentech’s patented ultra-small/low power analytical technology and include self-testing products like pregnancy test devices and ovulation test devices. And while the world was grappling with the diagnosis of COVID-19 in the early stages of the pandemic, Sugentech developed various kinds of diagnosis systems used in more than 120 countries. The company has demonstrated its prowess by going for third party evaluation from the first day and pursued compliance/registration of devices in each country. These products include RDT Ag and Ab tests, COVID-19 neutralizing efficacy ELISA and time-resolved fluorescence reader based ones and are FDA, EUA, and CE COC approved. Sugentech COVID -19 products have been registered in more than 100 countries and provided very robust and reliable performance with strong quality management to fight against COVID-19” says Dr. Lee. “This was a significant success of ours with good capability and they became our strong proponents of the diagnosis which was really required.”
Dr. Lee believes that the product is the king in the IVD world, and that’s what has propelled Sugentech to come up with first of its kind products. The Microalbumin/ACR ratio test on mobile App integrated SurealySmart system makes 24 hours urine test easier, comfortable, precise and affordable, and identifying 120 allergens at once with tiny volume of blood on Sblot full automated Lab system, or even the active TB blood diagnosis in less than 15 minutes. Soon, the company is planning to launch its dementia and periodontitis diagnosis devices.